Navigation Links
First Warning Systems, Inc., Retains Joshua D.I. Ellenhorn, M.D., as Principal Investigator
Date:8/26/2013

tems CEO Rob Royea says that Ellenhorn’s proven dedication to providing the highest quality of surgical care with an emphasis on a personalized approach to the individual patient aligns perfectly with the FWS mission. The company has devoted years of clinical research and significant funding toward the development of a process that promotes a proactive, compassionate, personalized approach to patient wellness and breast health.

“Through the guidance of Dr. Joshua Ellenhorn, we will be able to begin our final round of clinical validation trials later this year,” said Royea. “That brings us closer to a launch in Singapore and Asia by mid 2014, with Europe and the US to follow shortly thereafter. With the recent mandate requiring dense breast notification for patients here in the US and an epidemic of breast cancer in Asia, the release of this technology could not be more timely.”

With extensive clinical trials, and years of advanced algorithm refinement completed, FWS' patented intelligent predictive models are projected to improve accuracy for breast cancer assessment to over 75 percent. Unlike mammography and ultrasound which only image tissue characteristics, the FWS system detects tissue alterations down to the cellular level allowing for earlier, safer, more accurate cancer prediction for woman of all ages and tissue types. Ultimately, the FWS system is intended to reduce the number of necessary radiation procedures, while eliminating potentially unnecessary surgeries.

Designed to fit a wearable garment similar to a sports bra, FWS anticipates bringing their technology to market for an affordable price that will make it widely accessible to all markets.

To learn more, visit http://www.firstwarningsystems.com/.

About First Warning Systems Process
Dynamic thermal readings of breast tissue cellular changes creates a
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
4. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
5. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
6. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
7. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
8. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
9. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
10. Amgen Announces 2012 First Quarter Dividend
11. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 2015 , ... Rainbow Scientific, Inc. (RSI), a North American ... BI’s line of human mesenchymal stem cell (hMSC) differentiation media, MSC go ... complete system for multipotency evaluation of hMSCs and reliable induction of hMSCs into ...
(Date:7/28/2015)... ... ... The new Xsample 530 sample changer for vials can be used with Anton ... from less than 12,000 mPas (internal air) up to 36,000 (external air) – and can ... eye about Xsample 530 is its removable magazine, which is easily lifted off its hub ...
(Date:7/28/2015)... , July 21, 2015 ... has announced the addition of the "Analysis ... report to their offering. Globally, flow ... including immuno-phenotyping, cell proliferation, cancer, and stem cells. ... clinical applications primarily because of demand from underdeveloped ...
(Date:7/28/2015)...  Kerastem Technologies announce that the Company has received ... For Biologics Evaluation and Research (CBER) Office of Cellular, ... investigating the safety and feasibility of the Company,s technology ... baldness (androgenic alopecia). The phase II study, ... in Europe and ...
Breaking Biology Technology:Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3New Moves in Automatic Sample Handling: Introducing Xsample 530 2Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2
... on March 14 at 8:00 a.m. PDT ... ... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing products ... year ended December 31, 2007., "Our achievements in 2007 have advanced ...
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP) announced ... agreement with privately held Rex Medical, LP ("Rex,Medical") ... the,Option(TM) inferior vena cava (IVC) filter, a medical ... cava to prevent pulmonary embolism,(PE)., According to ...
... Calif., March 13 Bionovo, Inc.,(Nasdaq: BNVI ... Ph.D., to,the company,s Board of Directors. Dr. Butler ... and in particular in,advancing cancer drug development and ... have George on board as we move into ...
Cached Biology Technology:Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 6Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 7Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 8Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 2Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 3Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 4Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 5Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 6George Butler Joins Bionovo's Board of Directors 2George Butler Joins Bionovo's Board of Directors 3
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... ice-free region of Antarctica have discovered the last traces ... the interior of the southernmost continent before temperatures began ... abrupt and dramatic climate cooling of 8 degrees Celsius, ... 14 million years ago, forced the extinction of tundra ...
... an Indian open-pit coal mine could be the oldest Asian ... monkeys, apes and humans, say researchers from Duke University and ... square inch in size, the teeth are about 54.5 million ... than modern dwarf lemurs weighing about 2 to 3 ounces. ...
... studies presented at the XVII International AIDS Conference in ... of an impurity called ethyl methanesulfonate (EMS). The ... of the manufacturing of mesylate salts, which are contained ... The studies were designed to determine the impact of ...
Cached Biology News:Antarctic fossils paint a picture of a much warmer continent 2Antarctic fossils paint a picture of a much warmer continent 3Antarctic fossils paint a picture of a much warmer continent 4Antarctic fossils paint a picture of a much warmer continent 5Little teeth suggest big jump in primate timeline 2Landmark studies assess risk of exposure to elevated levels of EMS confirm clear toxicity threshold 2
... signaling of the members of the GPCR ... alternative splicing--which has important implications for drug ... a classical expression profiling and at the ... forms of the gene that are expressed ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Apoptosis is an evolutionarily conserved form ... cellular process. The central component of ... enzymes called caspases. These enzymes participate ... triggered in response to pro-apoptotic signals and ...
... Serum-free adapted Sf9 derivative for high-yield protein ... Cells are derived from a high-yielding clone ... Novagen serum-free TriEx Insect Cell Medium, these ... protein yields by either baculovirus infection or ...
Biology Products: